Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs).

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs).
复制标题

发现一种针对胃肠道间质瘤 (GIST) 的高选择性 KIT 激酶主要 V559D 突变抑制剂

DOI:
10.18632/oncotarget.22624
复制
发表时间:
2017-12-19
期刊:
影响因子:
--
通讯作者:
Liu J
Liu J
中科院分区:
其他
文献类型:
--
作者:
Yu K;Liu X;Jiang Z;Hu C;Zou F;Chen C;Ge J;Wu J;Liu X;Wang A;Wang W;Wang W;Qi Z;Wang B;Wang L;Yan H;Wang J;Ren T;Tang J;Liu Q;Liu J

文献摘要

参考文献

被引文献

相似文献

KIT激酶V559 D突变是胃肠道间质瘤(GIST)中最常见的原发性功能获得性突变。在这里,我们报道了一种高度选择性的KIT V559 D抑制剂CHMFL-KIT-031,其在生化测定(IC 50:28 nM vs 168 nM; Kd:266 nM vs 6640 nM)和细胞(EC 50:176 nM vs 2000 nM for pY 703)检查中显示出比KIT wt约10-20倍的选择性。它还显示出比其他初级突变体如L576 P和次级突变体包括T670 I、V654 A(ATP结合口袋)以及N822 K和D816 V(激活环)高15 ~ 400倍的选择性。此外,在KINOMEScan™测定中,它在468种激酶/突变体中表现出0.01的选择性S评分(1)。CHMFL-KIT-031对细胞中KIT V559 D介导的信号传导途径和体内抗肿瘤活性显示出强效抑制作用(肿瘤生长抑制:68.5%)。其上级选择性将使其成为进一步剖析GIST中KIT V559 D介导的病理学的良好药理学工具。
KIT kinase V559D mutation is the most prevalent primary gain-of-function mutation in Gastrointestinal Stromal Tumors (GISTs). Here we reported a highly selective KIT V559D inhibitor CHMFL-KIT-031, which displayed about 10-20 fold selectivity over KIT wt in the biochemical assay (IC50: 28 nM over 168 nM; Kd: 266 nM versus 6640 nM) and in cell (EC50: 176 nM versus 2000 nM for pY703) examination. It also displayed 15∼400-fold selectivity over other primary mutants such as L576P and secondary mutants including T670I, V654A (ATP binding pocket) as well as N822K and D816V (activation loop). In addition, it exhibited a selectivity S score (1) of 0.01 among 468 kinases/mutants in the KINOMEScan™ assay. CHMFL-KIT-031 showed potent inhibitory efficacy for KIT V559D mediated signaling pathways in cell and anti-tumor activity in vivo (Tumor Growth Inhibition: 68.5%). Its superior selectivity would make it a good pharmacological tool for further dissection of KIT V559D mediated pathology in the GISTs.
DOI: 10.1200/jco.2004.05.140
发表时间: 2004-09-15
影响因子: 45.3
作者:
Corless, CL;Fletcher, JA;Heinrich, MC
通讯作者: Heinrich, MC
DOI: 10.1200/jco.2003.04.190
发表时间: 2003-12-01
影响因子: 45.3
作者:
Heinrich, MC;Corless, CL;Fletcher, JA
通讯作者: Fletcher, JA
DOI: 10.1007/s12032-011-0074-y
发表时间: 2012-09-01
期刊: MEDICAL ONCOLOGY
影响因子: 3.4
作者:
Emile, J. F.;Brahimi, S.;Aegerter, P.
通讯作者: Aegerter, P.
DOI: 10.1016/s0140-6736(12)61857-1
发表时间: 2013-01-26
期刊: Lancet (London, England)
影响因子: --
作者:
Demetri GD;Reichardt P;Kang YK;Blay JY;Rutkowski P;Gelderblom H;Hohenberger P;Leahy M;von Mehren M;Joensuu H;Badalamenti G;Blackstein M;Le Cesne A;Schöffski P;Maki RG;Bauer S;Nguyen BB;Xu J;Nishida T;Chung J;Kappeler C;Kuss I;Laurent D;Casali PG;GRID study investigators
通讯作者: GRID study investigators
DOI: 10.1038/nbt1068
发表时间: 2005-03-01
影响因子: 46.9
作者:
Fabian, MA;Biggs, WH;Lockhart, DJ
通讯作者: Lockhart, DJ